Latest by Richard Jefferys
Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.
Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.
Researchers found a higher set point viral load prior to antiretroviral treatment (ART) was associated with a larger HIV reservoir, while a longer duration of viral suppression due to ART was associated with a smaller reservoir.
"We believe this is one of the first immune-based therapies to show a very profound reduction in inflammatory markers in the setting of treated HIV," Priscilla Hsue, M.D. states.
New research shows that it may be possible to identify many latently infected CD4 T cells due to expression of a particular cell surface protein.
Richard Jefferys analyzes key presentations from this year's Conference on Retroviruses and Opportunistic Infections.
HIV cure researchers seek out markers that would allow the specific targeting of cells harboring latent HIV. Enter a new candidate: interferon-induced transmembrane protein 1 (IFITM1).
"The results of the study appear very encouraging, and the researchers are hoping to rapidly evaluate whether they have any relevance to humans," Richard Jefferys writes. "A small clinical trial of the anti-α4β7 antibody vedolizumab, which is FDA-app...
One of the more futuristic-sounding ideas for curing HIV involves removing the genome of the virus from the genome of the cells into which it has integrated. On paper, the idea is very appealing, but there are a multitude of challenges.
The FDA-approved drug disulfiram (Antabuse) may be able to awaken hidden HIV -- in a small, but significant way -- according to results of a clinical trial in 30 HIV-positive individuals on antiretroviral therapy.